GlassScriptPhysician profile
Reuel M Aspacio
NPI 1366420887
$7,678.32
in general payments reported to CMS, 2019-2025
35 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,824 · 2020: $345 · 2021: $169 · 2022: $404 · 2023: $827 · 2024: $1,389 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,623 · Education: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,623.10 |
| Education | $312.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,042.33 | 2020-2025 | Bimzelx, Cimzia |
| Merz North America, INC. | $767.35 | 2019-2025 | Xeomin |
| Galderma Laboratories, L.P. | $740.90 | 2019-2025 | Aklief, Dysport |
| Abbvie INC. | $735.88 | 2019-2025 | |
| Genzyme Corporation | $619.13 | 2019-2025 | |
| Janssen Biotech, INC. | $517.48 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $475.48 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $449.13 | 2019-2025 | Siliq, Targretin, Cabtreo |
| Pfizer INC. | $399.69 | 2019-2025 | |
| Leo Pharma INC. | $379.08 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $249.27 | 2022-2025 | Taltz, Ebglyss |
| Mayne Pharma Commercial LLC | $225.92 | 2019-2020 | |
| Dermira, INC. | $186.90 | 2019-2021 | |
| Amgen INC. | $121.03 | 2019-2020 | |
| Celgene Corporation | $112.37 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $66.10 | 2020 | |
| Sandoz INC. | $63.31 | 2019-2020 | |
| Incyte Corporation | $61.93 | 2022-2025 | Opzelura |
| Almirall LLC | $61.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $60.89 | 2022-2025 | Sotyktu |
| Allergan, INC. | $58.90 | 2019 | |
| Arcutis Biotherapeutics, INC. | $44.61 | 2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $31.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.17 | 2025 | |
| Botanix Sb INC | $27.73 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $22.88 | 2019 | |
| Dermavant Sciences, INC. | $18.11 | 2023 | Vtama |
| Epi Health, LLC | $17.87 | 2019 | |
| Genentech USA, INC. | $15.40 | 2019 | |
| Sensus Healthcare, INC. | $15.00 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.71 | 2019 | |
| Strata Skin Sciences, INC. | $12.28 | 2019 | |
| Journey Medical Corporation | $11.21 | 2019 | |
| Merck Sharp & Dohme LLC | $11.14 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reuel Aspacio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.